Get set for 2025: Mastering the new EU HTA statistical guidelines
By AmerisourceBergen
Don't miss this on-demand webinar featuring Michael Hennig, PhD, Senior Director, Expertise Line Head HTA Statistics at Cencora PharmaLex, and Ruairi O'Donnell, PhD, EU HTA Lead at Cencora, as they shed light on the guidelines for statistical analysis transforming the landscape of European health technology assessment (HTA).
Scheduled to take effect in January 2025 for oncology and ATMP, these guidelines emphasize evidence synthesis and statistical methods for merging data on study drugs.
In this interactive session, including a live Q&A with the audience, our experts dive into the intricacies of these guidelines - their evolution, stakeholder involvement, implementation challenges, innovative approaches, adaptability to emerging trends - and discuss their potential impact on decision-making processes within healthcare systems across Europe.
Scheduled to take effect in January 2025 for oncology and ATMP, these guidelines emphasize evidence synthesis and statistical methods for merging data on study drugs.
In this interactive session, including a live Q&A with the audience, our experts dive into the intricacies of these guidelines - their evolution, stakeholder involvement, implementation challenges, innovative approaches, adaptability to emerging trends - and discuss their potential impact on decision-making processes within healthcare systems across Europe.
Michael Hennig, Ph.D.
Senior Director, Expertise Line Head HTA Statistics, Cencora PharmaLex
Ruairi O’Donnell, Ph.D.
EU HTA Lead, Cencora
Topics:
Consulting
